CR10914A - Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor - Google Patents
Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitorInfo
- Publication number
- CR10914A CR10914A CR10914A CR10914A CR10914A CR 10914 A CR10914 A CR 10914A CR 10914 A CR10914 A CR 10914A CR 10914 A CR10914 A CR 10914A CR 10914 A CR10914 A CR 10914A
- Authority
- CR
- Costa Rica
- Prior art keywords
- inhibitor
- methods
- unit dose
- dose formulations
- treating thrombosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87379206P | 2006-12-08 | 2006-12-08 | |
US94762907P | 2007-07-02 | 2007-07-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR10914A true CR10914A (es) | 2009-08-12 |
Family
ID=39110529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR10914A CR10914A (es) | 2006-12-08 | 2009-07-06 | Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor |
Country Status (19)
Country | Link |
---|---|
US (1) | US8404724B2 (es) |
EP (1) | EP2101760B1 (es) |
KR (1) | KR101472765B1 (es) |
CN (1) | CN105193799A (es) |
AU (1) | AU2007333377B2 (es) |
CA (2) | CA2913963A1 (es) |
CO (1) | CO6220933A2 (es) |
CR (1) | CR10914A (es) |
EC (1) | ECSP099501A (es) |
ES (1) | ES2409090T3 (es) |
HK (1) | HK1134031A1 (es) |
IL (1) | IL199219A (es) |
MA (1) | MA31086B1 (es) |
NI (1) | NI200900145A (es) |
NZ (1) | NZ578180A (es) |
PT (1) | PT2101760E (es) |
RU (2) | RU2452484C2 (es) |
SG (1) | SG10201504425SA (es) |
WO (1) | WO2008073670A2 (es) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001064642A2 (en) * | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
JP5020073B2 (ja) | 2004-06-18 | 2012-09-05 | ミレニアム ファーマシューティカルズ インク. | 第Xa因子阻害剤 |
US7696352B2 (en) * | 2004-06-18 | 2010-04-13 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
WO2006045503A1 (en) | 2004-10-19 | 2006-05-04 | Lonza Ag | Method for solid phase peptide synthesis |
SI1940786T1 (sl) | 2005-09-16 | 2010-11-30 | Arrow Therapeutics Ltd | Bifenilni derivati in njihova uporaba pri zdravljenju hepatitisa C |
WO2007112367A2 (en) * | 2006-03-27 | 2007-10-04 | Portola Pharmaceuticals, Inc. | Potassium channel modulators and platelet procoagulant activity |
TW200813017A (en) | 2006-05-05 | 2008-03-16 | Millennium Pharm Inc | Factor XA inhibitors |
WO2008057972A1 (en) * | 2006-11-02 | 2008-05-15 | Millennium Pharmaceuticals, Inc. | Methods of synthesizing pharmaceutical salts of a factor xa inhibitor |
AU2008205093A1 (en) * | 2007-01-05 | 2008-07-17 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
CN103071154A (zh) | 2007-04-13 | 2013-05-01 | 千年药品公司 | 用起因子xa抑制剂作用的化合物的组合抗凝治疗 |
EP2146705B1 (en) * | 2007-05-02 | 2014-03-05 | Portola Pharmaceuticals, Inc. | Combination therapy with a compound acting as a platelet adp receptor inhibitor |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
US8273900B2 (en) | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
US20120121515A1 (en) | 2009-03-13 | 2012-05-17 | Lenny Dang | Methods and compositions for cell-proliferation-related disorders |
CA2758071C (en) | 2009-04-06 | 2018-01-09 | Agios Pharmaceuticals, Inc. | Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use |
KR101712035B1 (ko) | 2009-06-29 | 2017-03-03 | 아지오스 파마슈티컬스 아이엔씨. | 치료용 화합물 및 조성물 |
ES2605801T3 (es) | 2009-07-15 | 2017-03-16 | Portola Pharmaceuticals, Inc. | Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia |
EP3561077B1 (en) | 2009-10-21 | 2022-12-21 | Les Laboratoires Servier | Methods for cell-proliferation-related disorders |
US8742120B2 (en) | 2009-12-17 | 2014-06-03 | Millennium Pharmaceuticals, Inc. | Methods of preparing factor xa inhibitors and salts thereof |
WO2011084519A1 (en) | 2009-12-17 | 2011-07-14 | Millennium Pharmaceuticals, Inc. | Methods of synthesizing factor xa inhibitors |
EP2513094B1 (en) | 2009-12-17 | 2015-12-16 | Millennium Pharmaceuticals, Inc. | Crystalline salts of a factor xa inhibitor |
EA015918B1 (ru) * | 2010-03-03 | 2011-12-30 | Дмитрий Геннадьевич ТОВБИН | УРЕТАНЫ, МОЧЕВИНЫ, АМИДЫ И РОДСТВЕННЫЕ ИНГИБИТОРЫ ФАКТОРА Xa |
TW201221128A (en) | 2010-09-01 | 2012-06-01 | Portola Pharm Inc | Crystalline forms of a factor Xa inhibitor |
MX2013006900A (es) | 2010-12-17 | 2013-10-17 | Agios Pharmaceuticals Inc | Nuevos derivados n-(4-(azetidina-1-carbonil)fenil)-(hetero-)arilsu lfonamida como moduladores piruvato quinasa m2 (pmk2). |
ES2569712T3 (es) | 2010-12-21 | 2016-05-12 | Agios Pharmaceuticals, Inc. | Activadores de PKM2 bicíclicos |
TWI549947B (zh) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
SG194697A1 (en) | 2011-05-03 | 2013-12-30 | Agios Pharmaceuticals Inc | Pyruvate kinase activators for use in therapy |
CA2834692A1 (en) | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in therapy |
CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
WO2013033370A1 (en) * | 2011-08-31 | 2013-03-07 | Portola Pharmaceuticals, Inc. | Prevention and treatment of thrombosis in medically ill patients |
US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
US9200268B2 (en) * | 2012-12-27 | 2015-12-01 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
US20140346397A1 (en) | 2012-12-27 | 2014-11-27 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US10376510B2 (en) | 2013-07-11 | 2019-08-13 | Agios Pharmaceuticals, Inc. | 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer |
US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
GB201314452D0 (en) | 2013-08-13 | 2013-09-25 | Ostara Biomedical Ltd | Embryo implantation |
WO2015054662A1 (en) | 2013-10-10 | 2015-04-16 | Eastern Virginia Medical School | 4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives as 12-lipoxygenase inhibitors |
GB201322777D0 (en) | 2013-12-20 | 2014-02-05 | Algipharma As | Use of alginate oligomers as blood anticoagulants |
JP6564796B2 (ja) | 2014-03-14 | 2019-08-21 | アジオス ファーマシューティカルズ, インコーポレイテッド | 治療活性化合物の医薬組成物 |
GB201501302D0 (en) | 2015-01-27 | 2015-03-11 | Ostara Biomedical Ltd | Embryo implantation |
EP4344703A1 (en) | 2015-06-11 | 2024-04-03 | Agios Pharmaceuticals, Inc. | Methods of using pyruvate kinase activators |
WO2016205062A1 (en) * | 2015-06-15 | 2016-12-22 | Shifa Biomedical Corporation | Antithrombotic therapies |
GB201517523D0 (en) | 2015-10-05 | 2015-11-18 | Ostara Biomedical Ltd | Methods and compositions for managing reproduction |
EP3362065B1 (en) | 2015-10-15 | 2024-04-03 | Les Laboratoires Servier | Combination therapy comprising ivosidenib, cytarabine and daunorubicin or idarubicin for treating acute myelogenous leukemia |
LT3362066T (lt) | 2015-10-15 | 2022-02-10 | Les Laboratoires Servier Sas | Kombinuota terapija, skirta piktybinių susirgimų gydymui |
MA49566A (fr) | 2017-07-11 | 2020-05-20 | Vertex Pharma | Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques |
WO2019071073A1 (en) | 2017-10-06 | 2019-04-11 | Forma Therapeutics, Inc. | INHIBITION OF THE SPECIFIC PEPTIDASE OF UBIQUITIN |
EA201800084A1 (ru) * | 2018-01-19 | 2019-07-31 | Общество С Ограниченной Ответственностью "Фармадиол" | НОВЫЕ АМИДИНЫ-ИНГИБИТОРЫ ФАКТОРА Ха |
US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
US20210277357A1 (en) * | 2018-06-15 | 2021-09-09 | Naing Bijaj | Methods of detection of mechanically-activated platelet activation and uses thereof |
DK3860989T3 (da) | 2018-10-05 | 2023-05-01 | Forma Therapeutics Inc | Kondenserede pyrroliner der fungerer som inhibitorer af ubiquitin-specifik protease 30 (usp30) |
AR120680A1 (es) | 2019-12-06 | 2022-03-09 | Vertex Pharma | Tetrahidrofuranos sustituidos como moduladores de canales de sodio |
EP4085056A1 (en) | 2020-01-03 | 2022-11-09 | Berg LLC | Polycyclic amides as ube2k modulators for treating cancer |
WO2022256622A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0813834B2 (ja) * | 1990-08-01 | 1996-02-14 | 日東紡績株式会社 | トリペプチド誘導体及びそれを有効成分とする蛋白分解酵素阻害剤 |
GB9226238D0 (en) | 1992-12-16 | 1993-02-10 | Scherer Ltd R P | Encapsulation apparatus and process |
YU8395A (sh) * | 1994-02-14 | 1998-07-10 | Kirin Brewery Company | Protein sa tpo aktivnošću |
AU2055500A (en) * | 1998-12-23 | 2000-07-31 | Eli Lilly And Company | Aromatic amides |
US6844367B1 (en) * | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
WO2001064642A2 (en) * | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
GB0021497D0 (en) * | 2000-09-01 | 2000-10-18 | Novartis Res Foundation | Compounds and their use |
US20040077690A1 (en) * | 2000-09-29 | 2004-04-22 | Bing-Yan Zhu | Quaternary amidino based inhibitors of factor xa |
CA2627086C (en) * | 2005-11-08 | 2016-04-05 | Millennium Pharmaceuticals, Inc. | Novel pharmaceutical salts and polymorphs of a factor xa inhibitor |
-
2007
- 2007-11-15 CA CA2913963A patent/CA2913963A1/en not_active Abandoned
- 2007-11-15 RU RU2009126147/15A patent/RU2452484C2/ru not_active IP Right Cessation
- 2007-11-15 AU AU2007333377A patent/AU2007333377B2/en not_active Ceased
- 2007-11-15 WO PCT/US2007/084887 patent/WO2008073670A2/en active Application Filing
- 2007-11-15 NZ NZ578180A patent/NZ578180A/en not_active IP Right Cessation
- 2007-11-15 CN CN201510530619.8A patent/CN105193799A/zh active Pending
- 2007-11-15 EP EP07864488A patent/EP2101760B1/en not_active Revoked
- 2007-11-15 PT PT78644887T patent/PT2101760E/pt unknown
- 2007-11-15 KR KR1020097014306A patent/KR101472765B1/ko active IP Right Grant
- 2007-11-15 SG SG10201504425SA patent/SG10201504425SA/en unknown
- 2007-11-15 CA CA2671502A patent/CA2671502C/en not_active Expired - Fee Related
- 2007-11-15 ES ES07864488T patent/ES2409090T3/es active Active
- 2007-12-07 US US11/999,957 patent/US8404724B2/en not_active Expired - Fee Related
-
2009
- 2009-06-07 IL IL199219A patent/IL199219A/en active IP Right Grant
- 2009-07-06 CR CR10914A patent/CR10914A/es unknown
- 2009-07-08 EC EC2009009501A patent/ECSP099501A/es unknown
- 2009-07-08 MA MA32076A patent/MA31086B1/fr unknown
- 2009-07-08 CO CO09070741A patent/CO6220933A2/es not_active Application Discontinuation
- 2009-07-21 NI NI200900145A patent/NI200900145A/es unknown
-
2010
- 2010-02-08 HK HK10101405.5A patent/HK1134031A1/xx not_active IP Right Cessation
-
2012
- 2012-02-10 RU RU2012104816/15A patent/RU2012104816A/ru not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US8404724B2 (en) | 2013-03-26 |
CN105193799A (zh) | 2015-12-30 |
IL199219A (en) | 2013-10-31 |
CO6220933A2 (es) | 2010-11-19 |
WO2008073670A2 (en) | 2008-06-19 |
EP2101760B1 (en) | 2013-02-27 |
CA2671502C (en) | 2017-01-24 |
KR101472765B1 (ko) | 2014-12-15 |
RU2452484C2 (ru) | 2012-06-10 |
EP2101760A2 (en) | 2009-09-23 |
MA31086B1 (fr) | 2010-01-04 |
NI200900145A (es) | 2010-11-29 |
RU2009126147A (ru) | 2011-01-20 |
AU2007333377B2 (en) | 2014-01-16 |
NZ578180A (en) | 2012-02-24 |
CA2913963A1 (en) | 2008-06-19 |
RU2012104816A (ru) | 2013-08-20 |
AU2007333377A1 (en) | 2008-06-19 |
HK1134031A1 (en) | 2010-04-16 |
ES2409090T3 (es) | 2013-06-24 |
WO2008073670A3 (en) | 2008-11-27 |
ECSP099501A (es) | 2010-01-29 |
KR20090107499A (ko) | 2009-10-13 |
PT2101760E (pt) | 2013-05-07 |
CA2671502A1 (en) | 2008-06-19 |
US20080153876A1 (en) | 2008-06-26 |
SG10201504425SA (en) | 2015-07-30 |
IL199219A0 (en) | 2010-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR10914A (es) | Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor | |
SMT201700037B (it) | Nuovi inibitori pirrolici della s-nitrosoglutatione riduttasi come agenti terapeutici | |
IL272926A (en) | Antidotes for factor XA inhibitors and methods of using them | |
CY2019010I1 (el) | Νεες ενωσεις και συνθεσεις και μεθοδοι χρησης | |
SMT201600278B (it) | Inibitori della benzossazolo chinasi e metodi d'uso | |
BRPI0812562A2 (pt) | composições terapêuticas anti-cd20 e métodos | |
ATE531720T1 (de) | Aza-benzofuranylverbindungen und anwendungsverfahren dafür | |
CY2014011I1 (el) | Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης | |
BRPI0907109A2 (pt) | lenço dental e método | |
IL206891A0 (en) | Therapeutic inhibitors of pai-1 function and methods of their use | |
BRPI0714318A2 (pt) | Utilização de 2-benzoil-imidazopiridinas em terapêutica | |
EP2096927A4 (en) | THERAPEUTIC COMPOSITIONS AND METHODS OF TREATING WITH CAPSIANOSIDE COMPOUNDS | |
ZA200904758B (en) | Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor | |
DE102006062287A8 (de) | Duschabtrennung und Beschlag | |
ITMI20061218A1 (it) | Derivati pepticidi e loro attivita' terapeutica | |
FI8286U1 (fi) | Kunto- ja terapiaväline | |
ITMI20060625A1 (it) | Peptide antiangiogenico e suoi impieghi terapeutici | |
TH0601002495A (th) | สารผสมตามสูตรทางเภสัชกรรมและวิธีการของการบำบัดรักษาซึ่งใช้สิ่งดังกล่าว | |
TH0601006175B (th) | วิธีการรักษาและองค์ประกอบของวัคซีน สำหรับการบำบัดโรคแอมีลอยด์ | |
SE0400614D0 (sv) | Composition and method of treatment | |
SE0400709D0 (sv) | Composition and method of treatment | |
FI20041069A0 (fi) | Menetelmä kaasutukseen ja kaasutusyksikkö | |
EE200800070A (et) | HDAC inhibiitorite kasutamine lmfoomide raviks | |
FI20065210A0 (fi) | Diagnostisia ja terapeuttisia aineita | |
SE0401628D0 (sv) | Metabolic drug and methods of treatment |